

Mahmoud M Shehata

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1224184/mahmoud-m-shehata-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

1,076
citations

16
h-index

32
g-index

34
ext. papers

1,336
ext. citations

7.9
avg, IF

4.04
L-index

#	Paper	IF	Citations
33	Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection.. <i>PLoS Pathogens</i> , 2022 , 18, e1010219	7.6	4
32	In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine. <i>Molecules</i> , 2021 , 26,	4.8	9
31	Naturally Available Flavonoid Aglycones as Potential Antiviral Drug Candidates against SARS-CoV-2. <i>Molecules</i> , 2021 , 26,	4.8	16
30	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. <i>PLoS Pathogens</i> , 2021 , 17, e1009413	7.6	8
29	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. <i>Vaccines</i> , 2021 , 9,	5.3	15
28	Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate. <i>Pathogens</i> , 2021 , 10,	4.5	31
27	Improved Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. <i>Frontiers in Microbiology</i> , 2021 , 12, 611958	5.7	4
26	Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and studies. <i>Heliyon</i> , 2021 , 7, e07962	3.6	29
25	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. <i>Bioorganic Chemistry</i> , 2021 , 116, 105363	5.1	3
24	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. <i>Frontiers in Microbiology</i> , 2020 , 11, 596851	5.7	5
23	FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	47
22	Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. <i>Microbiology Resource Announcements</i> , 2020 , 9,	1.3	21
21	Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science. <i>Microorganisms</i> , 2020 , 8,	4.9	12
20	Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. <i>PLoS ONE</i> , 2020 , 15, e0241471	3.7	4
19	PA from a Recent H9N2 (G1-Like) Avian Influenza a Virus (AIV) Strain Carrying Lysine 367 Confers Altered Replication Efficiency and Pathogenicity to Contemporaneous H5N1 in Mammalian Systems. <i>Viruses</i> , 2020 , 12,	6.2	1
18	NextGen Voices: Science-inspired sustainable behavior. <i>Science</i> , 2019 , 364, 822-824	33.3	5
17	Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV. <i>Vaccines</i> , 2019 , 7,	5.3	24

16	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. <i>Emerging Microbes and Infections</i> , 2019 , 8, 103-108	18.9	36
15	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. <i>Viruses</i> , 2019 , 11,	6.2	29
14	A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice. <i>Pathogens</i> , 2019 , 8,	4.5	3
13	Isolation and Characterization of a Distinct Influenza A Virus from Egyptian Bats. <i>Journal of Virology</i> , 2019 , 93,	6.6	27
12	Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt. <i>Archives of Virology</i> , 2018 , 163, 359-364	2.6	18
11	Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. <i>Emerging Microbes and Infections</i> , 2017 , 6, e1	18.9	49
10	Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. <i>Eurosurveillance</i> , 2017 , 22,	19.8	35
9	Middle East respiratory syndrome coronavirus: a comprehensive review. <i>Frontiers of Medicine</i> , 2016 , 10, 120-36	12	35
8	Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. <i>Vaccine</i> , 2016 , 34, 218-224	4.1	9
7	Surveillance for Coronaviruses in Bats, Lebanon and Egypt, 2013-2015. <i>Emerging Infectious Diseases</i> , 2016 , 22, 148-50	10.2	8
6	Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus Isolated from a Dromedary Camel in Egypt. <i>Genome Announcements</i> , 2016 , 4,		14
5	Genetic and antigenic evolution of H9N2 avian influenza viruses circulating in Egypt between 2011 and 2013. <i>Archives of Virology</i> , 2014 , 159, 2861-76	2.6	43
4	Active surveillance for avian influenza virus, Egypt, 2010-2012. <i>Emerging Infectious Diseases</i> , 2014 , 20, 542-51	10.2	61
3	MERS coronaviruses in dromedary camels, Egypt. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1049-53	10.2	221
2	Anticancer activities of mushroom polysaccharides on chemically-induced colorectal cancer in rats. <i>Journal of Applied Pharmaceutical Science</i> , 2014 , 4,	2	2
1	Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. <i>Eurosurveillance</i> , 2013 , 18, pii=20574	19.8	247